LDL-C-lowering therapies reduce major vascular events in patients aged ≥75 y

Ann Intern Med. 2021 Apr;174(4):JC38. doi: 10.7326/ACPJ202104200-038. Epub 2021 Apr 6.

Abstract

Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637-43. 33186535.

Keywords: Anticholesteremic agents; Cholesterol, LDL, Ezetimibe; Risk reduction behavior.

Publication types

  • Comment

MeSH terms

  • Aged
  • Anticholesteremic Agents* / adverse effects
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol, LDL
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors